

# 2018 Oncology Resident Grand Rounds Day

**Tuesday, August 28, 2018**

**12:00 – 2:00 p.m.**

**A3-924 A/B, London Regional Cancer  
Program**

**Dr. Daniel Breadner**

**The Influence of MATE1 on Cisplatin Toxicity and Efficacy in Head and Neck Cancer Patients**

To provide a background on chemoradiation in head and neck cancers, including the toxicities and challenges of treatment and survivorship.

Introduce MATE1 single nucleotide polymorphisms (SNPs)  
Review results of LRCP cohort of patients with H&N cancer who received cisplatin and had MATE1 testing.  
Future projects.

**Dr. Laura Callan**

**Technical Consideration in Stereotactic Ablative Body Radiotherapy for High-Grade Neuroendocrine Lung Cancer**

To discuss the role of SABR for treatment of early-stage high-grade neuroendocrine lung cancer.

To discuss technical challenges associated with treating small, highly radioresponsive lung tumors using SABR and propose potential solutions.

**Dr. Hanbo Chen**

**Are Higher Radiation Doses Beneficial in Limited-Stage Small-Cell Lung Cancer? A Propensity Score-Matched Analysis**

To review existing evidence on thoracic radiotherapy for limited-stage small-cell lung cancer (LS-SCLC).

To describe the establishment of a retrospective institutional LS-SCLC database.

To compare high-dose conventionally-fractionated and lower-dose hypo-fractionated thoracic radiotherapy in LS-SCLC using the institutional database and propensity score methodology.

**Dr. Mark Corkum**

**Does “5+5” Equal Better Radiation Treatment Plans in Head and Neck Cancers?**

Describe the “5+5” rule in international consensus guidelines when contouring head and neck cancers.

Introduce the importance of quality radiation treatment plans in head and neck cancers.

Evaluate the quality of radiation treatment plans delivered at the LRCP using international guidelines.

**Dr. Rohann Correa**

**Renal Stereotactic Ablative Radiotherapy (SABR) in patients with a solitary kidney an individual-patient pooled analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK)**

Explain the rationale for treatment of renal cell carcinoma with SABR.

Describe unique management challenges faced by patients with solitary kidney RCC.

Present data on renal function and oncologic outcomes following SABR for solitary kidney RCC.

**Dr. Christopher Goodman**

**Dosimetric Evaluation of PSMA PET-delineated Dominant Intra-prostatic Lesion Simultaneous Infield Boosts**

With radiobiological modeling we investigate the dosimetric feasibility and benefit of a boost to the dominant intraprostatic lesion using GTVs defined by a novel molecular PET probe directed against prostate specific membrane antigen (PSMA).

**Dr. Wei Liu**

**Advanced Prostate Imaging of Recurrent Cancer After Radiotherapy (PICs): Interim results of a prospective, multi-centre trial**

To explore treatment options for recurrent prostate cancer after primary radiation therapy.

To explore current restaging options for recurrent prostate cancer.  
To learn about [18F]-DCFPyL PSMA PET.

**Dr. Adam Mutsaers**

**Radiation Peer Review Resourcing Costing at LHSC**

Review the Peer Review goals and process at LRCP.  
Learn about time and dollar implications of current practices.  
Discuss potential changes and next steps for Peer Review.

**Dr. John Patrick**

**An Immobilization System for Prone Breast Radiotherapy**

To develop and test the immobilization device

To calculate inter- and intra-fraction breast motion during prone-breast radiotherapy

**Dr. Tina Zhang**

**Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature**

To provide an evidence-based estimate of the relationship between cardiac dose and mortality in patients with non-small cell lung cancer (NSCLC).

To discuss the relationship between heart dose-volume constraints and cardiac toxicity and death in NSCLC.

To present gaps in current literature and indicate direction for future studies.